-+ 0.00%
-+ 0.00%
-+ 0.00%

Enlivex Prices $7.5 Million Registered Direct Offering

PUBT·11/16/2026 13:07:08
Listen to the news
Enlivex Prices $7.5 Million Registered Direct Offering
  • Enlivex entered a securities purchase agreement for a $7.5 million registered direct offering of ordinary shares or pre-funded warrants, with accompanying ordinary warrants.
  • Combined pricing is $1.315 per ordinary share or $1.314 per pre-funded warrant, a 10.5% premium to the November 13, 2026, closing price.
  • The $500,000 initial closing is expected November 17, 2026; ten $700,000 monthly closings run from December 1, 2026, through September 1, 2027.
  • Ordinary warrants are immediately exercisable at $1.578 per share, expire three years from initial closing and could generate $9 million if fully cash-exercised.
  • Net proceeds will fund clinical and development activities, potential acquisitions and in-licensing, and general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-120146), on November 16, 2026, and is solely responsible for the information contained therein.